Intercept Pharmaceuticals to buy $39.9 million of 3.25% convertibles

By Mary-Katherine Stinson

Lexington, Ky., Sept. 13 – Intercept Pharmaceuticals, Inc. has announced an agreement reached in private negotiations with certain noteholders to repurchase $39.9 million of its 3.25% convertible senior notes for $38.1 million in cash, according to a company release.

With this purchase and other previously announced transactions, Intercept has reduced its principal balance from to $113.7 million from $460 million, representing 75% of the debt maturing in 2023.

Intercept Pharmaceuticals is a New York-based biopharmaceutical company that focuses on therapeutics to treat progressive non-viral liver diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.